Share Us:

Biblio

Export 1094 results:

Tagged

Author Title Type [ Year

]

Filters: First Letter Of Keyword is H [Clear All Filters]

2016

F. Nafar, J Williams, B., and Mearow, K. M., “Astrocytes release HspB1 in response to amyloid-β exposure in vitro.”, J Alzheimers Dis, vol. 49, no. 1, pp. 251-63, 2016.

S. Eketjäll, Janson, J., Kaspersson, K., Bogstedt, A., Jeppsson, F., Fälting, J., Haeberlein, S. Budd, Kugler, A. R., Alexander, R. C., and Cebers, G., “AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1109-23, 2016.

M. Ibarria, Alegret, M., Valero, S., Morera, A., Guitart, M., Cañabate, P., Moreno, M., Lara, S., Diego, S., Hernández, J., Tantinyá, N., Vera, M., Hernandez, I., Becker, J. T., Ruiz, A., Boada, M., and Tárraga, L., “Beneficial Effects of an Integrated Psychostimulation Program in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 2, pp. 559-66, 2016.

T. Dziedzic, Pera, J., Klimkowicz-Mrowiec, A., Mroczko, B., and Slowik, A., “Biochemical and Radiological Markers of Alzheimer's Disease Progression.”, J Alzheimers Dis, vol. 50, no. 3, pp. 623-44, 2016.

A. Mishima, Nihashi, T., Ando, Y., Kawai, H., Kato, T., Ito, K., and Terasawa, T., “Biomarkers Differentiating Dementia with Lewy Bodies from Other Dementias: A Meta-Analysis.”, J Alzheimers Dis, vol. 50, no. 1, pp. 161-74, 2016.

A. Malishkevich, Marshall, G. A., Schultz, A. P., Sperling, R. A., Aharon-Peretz, J., and Gozes, I., “Blood-Borne Activity-Dependent Neuroprotective Protein (ADNP) is Correlated with Premorbid Intelligence, Clinical Stage, and Alzheimer's Disease Biomarkers.”, J Alzheimers Dis, vol. 50, no. 1, pp. 249-60, 2016.

A. Malishkevich, Marshall, G. A., Schultz, A. P., Sperling, R. A., Aharon-Peretz, J., and Gozes, I., “Blood-Borne Activity-Dependent Neuroprotective Protein (ADNP) is Correlated with Premorbid Intelligence, Clinical Stage, and Alzheimer's Disease Biomarkers.”, J Alzheimers Dis, vol. 50, no. 1, pp. 249-60, 2016.

P. Caffarra, Ghetti, C., Ruffini, L., Spallazzi, M., Spotti, A., Barocco, F., Guzzo, C., Marchi, M., and Gardini, S., “Brain Metabolism Correlates of the Free and Cued Selective Reminding Test in Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 51, no. 1, pp. 27-31, 2016.

F. Guillot, Kemppainen, S., Lavasseur, G., Miettinen, P. O., Laroche, S., Tanila, H., and Davis, S., “Brain-Specific Basal and Novelty-Induced Alternations in PI3K-Akt and MAPK/ERK Signaling in a Middle-Aged AβPP/PS1 Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1157-73, 2016.

H. - F. Wang, Wan, Y., Hao, X. - K., Cao, L., Zhu, X. - C., Jiang, T., Tan, M. - S., Tan, L., Zhang, D. - Q., Tan, L., and Yu, J. - T., “Bridging Integrator 1 (BIN1) Genotypes Mediate Alzheimer's Disease Risk by Altering Neuronal Degeneration.”, J Alzheimers Dis, vol. 52, no. 1, pp. 179-90, 2016.

E. Aso, Andrés-Benito, P., Carmona, M., Maldonado, R., and Ferrer, I., “Cannabinoid Receptor 2 Participates in Amyloid-β Processing in a Mouse Model of Alzheimer's Disease but Plays a Minor Role in the Therapeutic Properties of a Cannabis-Based Medicine.”, J Alzheimers Dis, vol. 51, no. 2, pp. 489-500, 2016.

M. Mäkelä, Paetau, A., Polvikoski, T., Myllykangas, L., and Tanskanen, M., “Capillary amyloid-β protein deposition in a population-based study (Vantaa 85+).”, J Alzheimers Dis, vol. 49, no. 1, pp. 149-57, 2016.

S. Chu, Xu, F., Su, Y., Chen, H., and Cheng, X., “Cerebral Amyloid Angiopathy (CAA)-Related Inflammation: Comparison of Inflammatory CAA and Amyloid-β-Related Angiitis.”, J Alzheimers Dis, vol. 51, no. 2, pp. 525-32, 2016.

S. Chu, Xu, F., Su, Y., Chen, H., and Cheng, X., “Cerebral Amyloid Angiopathy (CAA)-Related Inflammation: Comparison of Inflammatory CAA and Amyloid-β-Related Angiitis.”, J Alzheimers Dis, vol. 51, no. 2, pp. 525-32, 2016.

N. Wang, Allali, G., Kesavadas, C., Noone, M. L., Pradeep, V. G., Blumen, H. M., and Verghese, J., “Cerebral Small Vessel Disease and Motoric Cognitive Risk Syndrome: Results from the Kerala-Einstein Study.”, J Alzheimers Dis, vol. 50, no. 3, pp. 699-707, 2016.

D. Renard, Wacongne, A., Ayrignac, X., Charif, M., Fourcade, G., Azakri, S., Le Floch, A., Bouly, S., Marelli, C., Arquizan, C., Hirtz, C., Gabelle, A., Thouvenot, E., and Lehmann, S., “Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Cerebral Amyloid Angiopathy-Related Inflammation.”, J Alzheimers Dis, vol. 50, no. 3, pp. 759-64, 2016.

M. Carmona-Iragui, Fernández-Arcos, A., Alcolea, D., Piazza, F., Morenas-Rodriguez, E., Antón-Aguirre, S., Sala, I., Clarimón, J., Dols-Icardo, O., Camacho, V., Sampedro, F., Munuera, J., Nuñez-Marin, F., Lleo, A., Fortea, J., Gómez-Ansón, B., and Blesa, R., “Cerebrospinal Fluid Anti-Amyloid-β Autoantibodies and Amyloid PET in Cerebral Amyloid Angiopathy-Related Inflammation.”, J Alzheimers Dis, vol. 50, no. 1, pp. 1-7, 2016.

M. Bjerke, Kern, S., Blennow, K., Zetterberg, H., Waern, M., Börjesson-Hanson, A., Östling, S., Kern, J., and Skoog, I., “Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years.”, J Alzheimers Dis, vol. 49, no. 3, pp. 733-41, 2016.

K. E. Melah, Lu, S. Yuan- Fu, Hoscheidt, S. M., Alexander, A. L., Adluru, N., Destiche, D. J., Carlsson, C. M., Zetterberg, H., Blennow, K., Okonkwo, O. C., Gleason, C. E., N Dowling, M., Bratzke, L. C., Rowley, H. A., Sager, M. A., Asthana, S., Johnson, S. C., and Bendlin, B. B., “Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 3, pp. 873-86, 2016.

K. E. Melah, Lu, S. Yuan- Fu, Hoscheidt, S. M., Alexander, A. L., Adluru, N., Destiche, D. J., Carlsson, C. M., Zetterberg, H., Blennow, K., Okonkwo, O. C., Gleason, C. E., N Dowling, M., Bratzke, L. C., Rowley, H. A., Sager, M. A., Asthana, S., Johnson, S. C., and Bendlin, B. B., “Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 3, pp. 873-86, 2016.

G. Novak, Fox, N., Clegg, S., Nielsen, C., Einstein, S., Lu, Y., Tudor, I. Cristina, Gregg, K., Di, J., Collins, P., Wyman, B. T., Yuen, E., Grundman, M., H Brashear, R., and Liu, E., “Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1123-34, 2016.

G. Novak, Fox, N., Clegg, S., Nielsen, C., Einstein, S., Lu, Y., Tudor, I. Cristina, Gregg, K., Di, J., Collins, P., Wyman, B. T., Yuen, E., Grundman, M., H Brashear, R., and Liu, E., “Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1123-34, 2016.

O. Godefroy, Bakchine, S., Verny, M., Delabrousse-Mayoux, J. - P., Roussel, M., and Pere, J. - J., “Characteristics of Alzheimer's Disease Patients with Severe Executive Disorders.”, J Alzheimers Dis, vol. 51, no. 3, pp. 815-25, 2016.

M. Kleinschmidt, Schoenfeld, R., Göttlich, C., Bittner, D., Metzner, J. Erich, Leplow, B., and Demuth, H. - U., “Characterizing Aging, Mild Cognitive Impairment, and Dementia with Blood-Based Biomarkers and Neuropsychology.”, J Alzheimers Dis, vol. 50, no. 1, pp. 111-26, 2016.

A. Madhavan, Schwarz, C. G., Duffy, J. R., Strand, E. A., Machulda, M. M., Drubach, D. A., Kantarci, K., Przybelski, S. A., Reid, R. I., Senjem, M. L., Gunter, J. L., Apostolova, L. G., Lowe, V. J., Petersen, R. C., Jack, C. R., Josephs, K. A., and Whitwell, J. L., “Characterizing White Matter Tract Degeneration in Syndromic Variants of Alzheimer's Disease: A Diffusion Tensor Imaging Study.”, J Alzheimers Dis, vol. 49, no. 3, pp. 633-43, 2016.

Pages